We are live on
!
Find out more
ARTV
Artiva Biotherapeutics
ARTV
ARTV
40 hedge funds and large institutions have $52.1M invested in Artiva Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
86% more capital invested
Capital invested by funds: $27.9M → $52.1M (+$24.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.65% less ownership
Funds ownership: 75.97% → 74.32% (-1.6%)
17% less funds holding
Funds holding: 48 → 40 (-8)
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Holders
40
Holders Change
-8
Holders Change %
-16.67%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
6
Increased
8
Reduced
16
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.72M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$315K |
| 3 |
Citigroup
New York
|
+$273K |
| 4 |
Renaissance Technologies
New York
|
+$212K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$128K |
Top Sellers
| 1 |
BlackRock
New York
|
-$512K |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$440K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$428K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$198K |
| 5 |
Goldman Sachs
New York
|
-$183K |
